• 1. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
• 2. Alt-proteins: A promising future
• 3. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 4. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 5. An aquatic host–guest complex between a supramolecular G-quadruplex and the anticancer drug doxorubicin?
  José M. Rivera,Mariana Martín-Hidalgo,Jean C. Rivera-Ríos Org. Biomol. Chem., 2012,10, 7562-7565

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyridines Imidazopyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyridines

Introduction to 2-chloro-5-methyl-3H-imidazo[4,5-bpyridine (CAS No. 116035-71-3)

2-chloro-5-methyl-3H-imidazo[4,5-bpyridine, identified by its Chemical Abstracts Service (CAS) number 116035-71-3, is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the imidazobipyridine class, a structural motif known for its versatile biological activities and potential therapeutic applications. The presence of both chloro and methyl substituents in its molecular framework enhances its reactivity, making it a valuable scaffold for the development of novel bioactive molecules.

The structural integrity of 2-chloro-5-methyl-3H-imidazo[4,5-bpyridine is characterized by a fused ring system consisting of an imidazole ring connected to a bipyridine moiety. This unique arrangement imparts distinct electronic and steric properties, which are critical for its interaction with biological targets. The chloro substituent at the 2-position and the methyl group at the 5-position contribute to the compound's pharmacophoric features, enabling it to modulate various biological pathways effectively.

In recent years, there has been a surge in research focused on developing small molecule inhibitors targeting cancer-related pathways. 2-chloro-5-methyl-3H-imidazo[4,5-bpyridine has emerged as a promising candidate in this domain due to its ability to interfere with key signaling cascades involved in tumor growth and progression. Preclinical studies have demonstrated its potential in inhibiting enzymes such as tyrosine kinases, which are overexpressed in many solid tumors. The compound's ability to selectively bind to these enzymes without significant off-target effects makes it an attractive lead for further development.

One of the most compelling aspects of 2-chloro-5-methyl-3H-imidazo[4,5-bpyridine is its role as a precursor in synthesizing more complex derivatives with enhanced pharmacological properties. Researchers have leveraged its structural framework to develop analogs that exhibit improved solubility, bioavailability, and target specificity. For instance, modifications at the 3-position of the imidazole ring have been explored to enhance binding affinity to protein targets. These structural optimizations have led to the discovery of several novel compounds that are currently undergoing preclinical evaluation for their anticancer efficacy.

The synthesis of 2-chloro-5-methyl-3H-imidazo[4,5-bpyridine involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and purity. Common synthetic routes include condensation reactions between appropriately substituted imidazole and bipyridine precursors, followed by functional group transformations such as chlorination and methylation. Advances in catalytic methods have further refined these synthetic pathways, making them more efficient and environmentally sustainable.

From a computational chemistry perspective, 2-chloro-5-methyl-3H-imidazo[4,5-bpyridine has been extensively studied using molecular modeling techniques to understand its interactions with biological targets. These studies have provided insights into the compound's binding mode, affinity, and potential side effects. Virtual screening approaches have been employed to identify additional derivatives with improved pharmacokinetic profiles. Such computational tools are indispensable in modern drug discovery pipelines, enabling researchers to prioritize promising candidates for experimental validation.

The pharmacological profile of 2-chloro-5-methyl-3H-imidazo[4,5-bpyridine has been evaluated across various in vitro and in vivo models. Initial studies have highlighted its ability to induce apoptosis in cancer cell lines by disrupting mitochondrial function and inhibiting anti-apoptotic proteins. Furthermore, its potential as an immunomodulatory agent has been explored, with evidence suggesting that it can enhance immune responses against tumor cells. These findings underscore the compound's multifaceted therapeutic potential.

In conclusion,2-chloro-5-methyl-3H-imidazo[4,5-bpyridine (CAS No. 116035-71-3) represents a significant advancement in pharmaceutical research due to its unique structural features and biological activities. Its role as a scaffold for developing novel anticancer agents underscores its importance in medicinal chemistry. As research continues to uncover new applications for this compound, it is likely that it will play an increasingly pivotal role in the development of next-generation therapeutics.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)